JP2007533330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533330A5 JP2007533330A5 JP2007527193A JP2007527193A JP2007533330A5 JP 2007533330 A5 JP2007533330 A5 JP 2007533330A5 JP 2007527193 A JP2007527193 A JP 2007527193A JP 2007527193 A JP2007527193 A JP 2007527193A JP 2007533330 A5 JP2007533330 A5 JP 2007533330A5
- Authority
- JP
- Japan
- Prior art keywords
- animals
- toxin
- antibody
- vancomycin
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001465754 Metazoa Species 0.000 description 19
- 108090001123 antibodies Proteins 0.000 description 13
- 102000004965 antibodies Human genes 0.000 description 13
- 101700023105 3L21 Proteins 0.000 description 11
- 241000699800 Cricetinae Species 0.000 description 11
- 101710037563 alpha-delta-Bgt-2 Proteins 0.000 description 10
- 101700080113 toxB Proteins 0.000 description 10
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 9
- 229960003165 Vancomycin Drugs 0.000 description 9
- 108010059993 Vancomycin Proteins 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 241000193163 Clostridioides difficile Species 0.000 description 6
- 210000002966 Serum Anatomy 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 102000004851 Immunoglobulin G Human genes 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 230000001147 anti-toxic Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- 201000008286 diarrhea Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 101700012833 3S11 Proteins 0.000 description 1
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101700057439 TOXA Proteins 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 101700041767 ctxA Proteins 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54235704P | 2004-02-06 | 2004-02-06 | |
| US61385404P | 2004-09-28 | 2004-09-28 | |
| PCT/US2005/003725 WO2006121422A2 (en) | 2004-02-06 | 2005-02-04 | Antibodies against clostridium difficile toxins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010169364A Division JP5319622B2 (ja) | 2004-02-06 | 2010-07-28 | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007533330A JP2007533330A (ja) | 2007-11-22 |
| JP2007533330A5 true JP2007533330A5 (pl) | 2010-09-24 |
| JP4588763B2 JP4588763B2 (ja) | 2010-12-01 |
Family
ID=36928722
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527193A Active JP4588763B2 (ja) | 2004-02-06 | 2005-02-04 | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用 |
| JP2010169364A Active JP5319622B2 (ja) | 2004-02-06 | 2010-07-28 | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用 |
| JP2013036855A Active JP5717300B2 (ja) | 2004-02-06 | 2013-02-27 | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010169364A Active JP5319622B2 (ja) | 2004-02-06 | 2010-07-28 | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用 |
| JP2013036855A Active JP5717300B2 (ja) | 2004-02-06 | 2013-02-27 | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US7625559B2 (pl) |
| EP (3) | EP1766093B1 (pl) |
| JP (3) | JP4588763B2 (pl) |
| KR (3) | KR101332927B1 (pl) |
| CN (1) | CN101014620B (pl) |
| AT (1) | ATE512986T1 (pl) |
| AU (1) | AU2005320349C1 (pl) |
| BE (1) | BE2017C023I2 (pl) |
| BR (1) | BRPI0507433C1 (pl) |
| CA (1) | CA2553946C (pl) |
| CY (3) | CY1111860T1 (pl) |
| DK (3) | DK1766093T3 (pl) |
| ES (3) | ES2643760T3 (pl) |
| HK (3) | HK1152048A1 (pl) |
| HR (1) | HRP20110599T1 (pl) |
| HU (3) | HUE024962T2 (pl) |
| LT (2) | LT2857418T (pl) |
| LU (1) | LUC00025I2 (pl) |
| MX (1) | MXPA06008839A (pl) |
| NL (1) | NL300881I2 (pl) |
| NO (2) | NO340300B1 (pl) |
| NZ (2) | NZ580828A (pl) |
| PL (3) | PL1766093T3 (pl) |
| PT (3) | PT1766093E (pl) |
| RS (1) | RS51908B (pl) |
| SI (3) | SI2270045T1 (pl) |
| WO (1) | WO2006121422A2 (pl) |
| ZA (1) | ZA200606516B (pl) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| WO2006121422A2 (en) * | 2004-02-06 | 2006-11-16 | University Of Massachusetts | Antibodies against clostridium difficile toxins and uses thereof |
| AU2005257527B9 (en) * | 2004-06-28 | 2009-03-05 | Japan Science And Technology Agency | Method of screening toxin-neutralizing peptide, STX2 inhibitory peptide and vero toxin-neutralizing agent |
| CA2592015A1 (en) * | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
| CA2659684A1 (en) | 2006-08-02 | 2008-02-07 | Johannes Gutenberg-Universitaet Mainz | Medicament for lct poisoning |
| KR101722305B1 (ko) | 2007-01-30 | 2017-03-31 | 에피백스, 인크. | 조절 ｔ 세포 에피토프, 그의 조성물 및 용도 |
| AU2014201846B2 (en) * | 2007-01-30 | 2016-07-07 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| US20080188007A1 (en) * | 2007-02-06 | 2008-08-07 | Meridian Life Science, Inc. | Fluorescent single chain antibody and its use in detection of analytes |
| CN101363867B (zh) * | 2008-05-26 | 2012-12-19 | 北京庄笛浩禾生物医学科技有限公司 | 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法 |
| WO2009154995A2 (en) * | 2008-05-27 | 2009-12-23 | Kyowa Hakko Kirin Co., Ltd. | Interleukin 10 receptor (il-10r) antibodies and methods of use |
| DE102008029688B4 (de) * | 2008-06-24 | 2016-06-23 | Biodics Gmbh | Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe |
| CN102365097A (zh) * | 2009-02-20 | 2012-02-29 | 卫生防护机构 | 艰难梭菌毒素的抗体 |
| US8889363B2 (en) | 2009-07-27 | 2014-11-18 | Biodics | Method for the detection and identification of a variant C. difficile strain in a sample |
| EP2459588B1 (de) * | 2009-07-27 | 2016-06-29 | BioDics GmbH | Verfahren zum nachweis und zur identifikation eines varianten c. difficile stammes in einer probe |
| WO2011063346A1 (en) * | 2009-11-20 | 2011-05-26 | Northshore University Health System Research Institute | Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| US8986697B2 (en) * | 2010-04-15 | 2015-03-24 | Progenics Pharmaceuticals, Inc. | Antibodies for the treatment of Clostridium difficile-associated infection and disease |
| RU2630663C9 (ru) * | 2010-04-15 | 2017-11-29 | Проджиникс Фармасьютикалс, Инк. | Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний |
| LT2753352T (lt) | 2010-09-03 | 2017-05-25 | Valneva Austria Gmbh | Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas |
| GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| CA2815888C (en) * | 2010-10-25 | 2020-06-30 | National Research Council Of Canada | Clostridium difficile-specific antibodies and uses thereof |
| CA2834402A1 (en) * | 2010-12-29 | 2012-07-05 | Cangene Corporation | Clostridium difficile antigens |
| US8906635B2 (en) | 2011-02-28 | 2014-12-09 | Northshore University Healthsystem | Methods of diagnosing Clostridium difficile infection |
| EP4365196A3 (en) | 2011-04-22 | 2024-08-07 | Wyeth LLC | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
| KR101955365B1 (ko) * | 2011-07-12 | 2019-03-07 | 필라델피아 헬스 앤드 에듀케이션 코포레이션 디/비/에이 드렉셀 유니버시티 컬리지 오브 메디슨 | 신규한 클로스트리듐 디피실(Clostridium Difficile) DNA 백신 |
| SG10201804809RA (en) | 2011-08-22 | 2018-07-30 | Cnj Holdings Inc | Clostridium difficile antibodies |
| SI2758432T1 (sl) * | 2011-09-16 | 2019-07-31 | Ucb Biopharma Sprl | Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile |
| US10364298B2 (en) | 2011-11-18 | 2019-07-30 | National Research Council Of Canada | Clostridium difficile lipoteichoic acid and uses thereof |
| JP6084631B2 (ja) | 2011-12-08 | 2017-02-22 | ノバルティス アーゲー | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン |
| DE102011121238A1 (de) * | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-antikörper gegen clostridium difficile toxine |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| TWI592422B (zh) * | 2012-03-02 | 2017-07-21 | 再生元醫藥公司 | 抗艱難梭狀芽孢桿菌毒素之人類抗體 |
| GB201206070D0 (en) | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| US20150259402A1 (en) * | 2012-10-19 | 2015-09-17 | Evec Inc. | Human antibody specific to toxin produced from clostridium difficile, or antigen-binding fragment thereof |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| CN105025926B (zh) * | 2012-11-28 | 2018-12-14 | Cnj控股公司 | 针对艰难梭菌的抗体 |
| US10160797B2 (en) | 2013-03-15 | 2018-12-25 | Sanofi Pasteur Biologics, Llc | Antibodies against Clostridium difficile toxins and methods of using the same |
| CA2909636C (en) * | 2013-04-19 | 2023-08-22 | Dena Lyras | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease |
| US9181632B1 (en) | 2013-09-09 | 2015-11-10 | Merck Sharp & Dohme Corp. | C.difficile toxin B CROP domain peptides, antibodies and complexes thereof |
| WO2015100409A2 (en) * | 2013-12-26 | 2015-07-02 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein |
| AU2015213593B2 (en) * | 2014-02-10 | 2020-09-03 | Igm Biosciences, Inc. | IgA multi-specific binding molecules |
| US20170065702A1 (en) | 2014-02-19 | 2017-03-09 | Cangene Corporation | Methods of modulating an immune response |
| RU2016138744A (ru) | 2014-04-10 | 2018-05-11 | Оби Фарма Инк. | Антитела, фармацевтические композиции и их применения |
| US10550437B2 (en) * | 2014-05-30 | 2020-02-04 | Case Western Reserve University | Clostridium difficile culture medium |
| US10513552B2 (en) | 2014-06-20 | 2019-12-24 | Immunimed Inc. | Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease |
| EP2957570B1 (en) | 2014-06-20 | 2019-04-17 | Immunimed Inc. | Polyclonal antibodies against clostridium difficile and uses thereof |
| US10533036B2 (en) * | 2015-02-19 | 2020-01-14 | Immune Biosolutions Inc | Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof |
| WO2016156474A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a |
| EP3277706A1 (en) | 2015-03-31 | 2018-02-07 | VHsquared Limited | Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b |
| CN105039262B (zh) * | 2015-07-10 | 2018-07-03 | 北京科兴中维生物技术有限公司 | 破伤风类毒素单克隆抗体及其应用 |
| AU2016315873B2 (en) | 2015-09-04 | 2022-08-18 | Primatope Therapeutics Inc. | Humanized anti-CD40 antibodies and uses thereof |
| MA44077A (fr) | 2015-12-15 | 2021-05-05 | Gilead Sciences Inc | Anticorps neutralisants le virus de l'immunodéficience humaine |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2018035407A1 (en) * | 2016-08-19 | 2018-02-22 | Enbiotix, Inc. | Bacteriophages for neutralizing toxins and methods of use thereof |
| WO2018237148A1 (en) | 2017-06-21 | 2018-12-27 | Gilead Sciences, Inc. | MULTISPECIFIC ANTIBODIES TARGETING HIV GP120 AND CD3 |
| WO2019204784A1 (en) * | 2018-04-19 | 2019-10-24 | First Light Biosciences, Inc. | Detection of targets |
| WO2020231930A1 (en) * | 2019-05-11 | 2020-11-19 | The Texas A&M University System | Protein inhibitors of clostridium difficile toxin b |
| WO2021219786A1 (en) * | 2020-04-30 | 2021-11-04 | Gottfried Himmler | Anti-toxin secretory iga2 preparation |
| CN111499738B (zh) * | 2020-06-03 | 2022-04-05 | 郑州师范学院 | 一种抗艰难梭菌肠毒素a的抗体 |
| CN114853896B (zh) * | 2020-11-30 | 2023-05-09 | 四川大学华西医院 | 一种抗糖基转移酶a亚单位的纳米抗体及其应用 |
| CN117720651B (zh) * | 2023-12-13 | 2024-05-31 | 北京新兴四寰生物技术有限公司 | 抗艰难梭菌毒素b的单克隆抗体及其应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879218A (en) * | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
| US5332583A (en) | 1987-11-24 | 1994-07-26 | Connaught Laboratories Limited | Vaccine containing genetically-detoxified pertussis holotoxin |
| US5244657A (en) | 1987-11-24 | 1993-09-14 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5358868A (en) | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5221618A (en) | 1987-11-24 | 1993-06-22 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
| US5231003A (en) * | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| AU668374B2 (en) * | 1991-12-10 | 1996-05-02 | Dana-Farber Cancer Institute | Reactive neutralizing human anti-GP120 recombinant antibody, DNA coding the same and use thereof |
| US5466672A (en) | 1992-12-04 | 1995-11-14 | Ophidian Pharmaceuticals, Inc. | Therapeutic use of clostridium difficile toxin A |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| BR9509903A (pt) | 1994-10-24 | 1997-11-25 | Ophidian Pharm Inc | Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial |
| GB9621295D0 (en) * | 1995-12-07 | 1996-11-27 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| AU746859B2 (en) | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
| DE19739685A1 (de) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
| EP2305293A3 (en) | 1997-10-20 | 2013-11-06 | Sanofi Pasteur Biologics Co. | Immunization against Clostridium difficile disease |
| US6733760B1 (en) * | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| DE60037896D1 (de) | 1999-07-29 | 2008-03-13 | Medarex Inc | Menschliche antikörper gegen her2/neu |
| US6984720B1 (en) | 1999-08-24 | 2006-01-10 | Medarex, Inc. | Human CTLA-4 antibodies |
| GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
| UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| TWI327597B (en) * | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| JP2005518789A (ja) * | 2002-01-28 | 2005-06-30 | メダレックス， インク． | 前立腺特異性膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体 |
| SI1487856T1 (sl) * | 2002-03-04 | 2010-12-31 | Imclone Llc | Äśloveĺ ka protitelesa specifiäśna za kdr (receptor z domeno kinaznega vkljuäśka) in njihove uporabe |
| AU2003219954B2 (en) * | 2002-03-21 | 2006-11-09 | Eli Lilly And Company | Antagonistic anti-hFas ligand human antibodies and fragments thereof |
| WO2003092630A2 (en) * | 2002-05-06 | 2003-11-13 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries |
| US7396913B2 (en) * | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
| TWI320716B (en) * | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
| ES2347239T3 (es) * | 2002-12-02 | 2010-10-27 | Amgen Fremont Inc. | Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos. |
| AU2003300680A1 (en) | 2002-12-10 | 2004-07-09 | Centre National De La Recherche Scientifique Cnrs | Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation |
| US20070003561A1 (en) * | 2003-07-08 | 2007-01-04 | Sorensen Anders P | Binding member towards pneumococcus surface adhesin a protein (psaa) |
| EP2865687A1 (en) * | 2003-12-10 | 2015-04-29 | E. R. Squibb & Sons, L.L.C. | IP-10 antibodies and their uses |
| WO2006121422A2 (en) * | 2004-02-06 | 2006-11-16 | University Of Massachusetts | Antibodies against clostridium difficile toxins and uses thereof |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
-
2005
- 2005-02-04 WO PCT/US2005/003725 patent/WO2006121422A2/en active Application Filing
- 2005-02-04 DK DK05857759.4T patent/DK1766093T3/da active
- 2005-02-04 CA CA2553946A patent/CA2553946C/en active Active
- 2005-02-04 EP EP05857759A patent/EP1766093B1/en active Active
- 2005-02-04 ES ES14194551.9T patent/ES2643760T3/es active Active
- 2005-02-04 KR KR1020117029761A patent/KR101332927B1/ko active IP Right Grant
- 2005-02-04 MX MXPA06008839A patent/MXPA06008839A/es active IP Right Grant
- 2005-02-04 PT PT05857759T patent/PT1766093E/pt unknown
- 2005-02-04 LT LTEP14194551.9T patent/LT2857418T/lt unknown
- 2005-02-04 KR KR1020067017771A patent/KR101332994B1/ko active IP Right Grant
- 2005-02-04 SI SI200531949T patent/SI2270045T1/sl unknown
- 2005-02-04 PL PL05857759T patent/PL1766093T3/pl unknown
- 2005-02-04 DK DK14194551.9T patent/DK2857418T3/en active
- 2005-02-04 PT PT141945519T patent/PT2857418T/pt unknown
- 2005-02-04 CN CN2005800041265A patent/CN101014620B/zh active Active
- 2005-02-04 SI SI200531344T patent/SI1766093T1/sl unknown
- 2005-02-04 ES ES05857759T patent/ES2366626T3/es active Active
- 2005-02-04 EP EP10010733.3A patent/EP2270045B8/en active Active
- 2005-02-04 ES ES10010733.3T patent/ES2533492T3/es active Active
- 2005-02-04 PT PT100107333T patent/PT2270045E/pt unknown
- 2005-02-04 HU HUE10010733A patent/HUE024962T2/en unknown
- 2005-02-04 US US11/051,453 patent/US7625559B2/en active Active
- 2005-02-04 NZ NZ580828A patent/NZ580828A/en unknown
- 2005-02-04 AU AU2005320349A patent/AU2005320349C1/en active Active
- 2005-02-04 BR BRPI0507433A patent/BRPI0507433C1/pt active IP Right Grant
- 2005-02-04 PL PL14194551T patent/PL2857418T3/pl unknown
- 2005-02-04 JP JP2007527193A patent/JP4588763B2/ja active Active
- 2005-02-04 PL PL10010733T patent/PL2270045T3/pl unknown
- 2005-02-04 DK DK10010733.3T patent/DK2270045T3/en active
- 2005-02-04 SI SI200532173T patent/SI2857418T1/en unknown
- 2005-02-04 KR KR1020127017138A patent/KR20120083534A/ko not_active Application Discontinuation
- 2005-02-04 EP EP14194551.9A patent/EP2857418B1/en active Active
- 2005-02-04 NZ NZ548821A patent/NZ548821A/en unknown
- 2005-02-04 RS RS20110361A patent/RS51908B/en unknown
- 2005-02-04 HU HUE14194551A patent/HUE034552T2/en unknown
- 2005-02-04 AT AT05857759T patent/ATE512986T1/de active
-
2006
- 2006-08-04 ZA ZA2006/06516A patent/ZA200606516B/en unknown
- 2006-08-23 NO NO20063767A patent/NO340300B1/no active Protection Beyond IP Right Term
-
2007
- 2007-09-25 HK HK11105869.4A patent/HK1152048A1/xx unknown
- 2007-09-25 HK HK07110397.1A patent/HK1102287A1/xx unknown
-
2009
- 2009-07-31 US US12/533,501 patent/US8236311B2/en active Active
- 2009-07-31 US US12/533,552 patent/US8257709B2/en active Active
-
2010
- 2010-07-28 JP JP2010169364A patent/JP5319622B2/ja active Active
-
2011
- 2011-08-11 HR HR20110599T patent/HRP20110599T1/hr unknown
- 2011-09-13 CY CY20111100872T patent/CY1111860T1/el unknown
-
2012
- 2012-06-07 US US13/490,757 patent/US8609111B2/en active Active
-
2013
- 2013-02-27 JP JP2013036855A patent/JP5717300B2/ja active Active
- 2013-11-14 US US14/080,598 patent/US9217029B2/en active Active
-
2015
- 2015-09-24 HK HK15109420.4A patent/HK1208873A1/xx unknown
- 2015-10-29 US US14/926,706 patent/US20160152694A1/en not_active Abandoned
-
2017
- 2017-06-27 NL NL300881C patent/NL300881I2/nl unknown
- 2017-06-27 HU HUS1700028C patent/HUS1700028I1/hu unknown
- 2017-06-28 BE BE2017C023C patent/BE2017C023I2/fr unknown
- 2017-06-28 CY CY2017022C patent/CY2017022I1/el unknown
- 2017-07-04 LU LU00025C patent/LUC00025I2/en unknown
- 2017-07-07 NO NO2017032C patent/NO2017032I1/no unknown
- 2017-07-11 LT LTPA2017022 patent/LTC2270045I2/lt unknown
- 2017-09-21 CY CY20171101001T patent/CY1119416T1/el unknown
-
2018
- 2018-03-19 US US15/924,703 patent/US20180208643A1/en not_active Abandoned
-
2020
- 2020-09-16 US US17/022,766 patent/US20210269511A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007533330A5 (pl) | ||
| FI101937B (fi) | Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmi sen cachectiinin kanssa | |
| ES2346184T3 (es) | Antagonistas de cd30 o cd30l para usar en el tratamiento de enfermedades antiinflamatorias cronicas y autoinmunes. | |
| ES2662519T3 (es) | Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos | |
| US5639455A (en) | Immunosuppressant | |
| CA2261630C (en) | Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease | |
| US6086874A (en) | Antitumor agent effect enhancer containing IL-6 antagonist | |
| EP3746119A1 (en) | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody | |
| ES2389930T3 (es) | Producción de anticuerpos monoclonales mediante transformación con VEB de células B | |
| JP2004510752A5 (pl) | ||
| UA101945C2 (uk) | Лікування злоякісного новоутворення за допомогою бевацизумабу | |
| TW200803895A (en) | Method of using IL6 antagonists with proteasome inhibitors | |
| JP2005506035A5 (pl) | ||
| EA034854B1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| CA2400106A1 (en) | Antibodies to human cd154 | |
| CN101815725A (zh) | 抗cd37抗体 | |
| UA85531C2 (uk) | Застосування il-18 інгібіторів для лікування або попередження пов'язаної з сепсисом дисфункції серця | |
| TW201942132A (zh) | 雙特異性抗體 | |
| WO2017185949A1 (zh) | 一种抗cd20靶向抗体 | |
| KR102500868B1 (ko) | 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도 | |
| HU211059B (en) | Method for producing pharmaceutical compositions usable for reducing immunglobulin e responses, containing human il-4 antibodies | |
| WO2014170811A2 (en) | Novel mutant l-asparaginases | |
| WO2001007082A1 (en) | Combination of an anti-ep-cam antibody with a chemotherapeutic agent | |
| JP2009524428A5 (pl) | ||
| Kontsek et al. | Mapping of two immunodominant structures on human interferon alpha 2c and their role in binding to cells |